Combined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancer-Reference-Cited by-同舟云学术

Combined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancer

Published:2023 Issue:15 Volume:11 Page:3453-3472
ISSN:2050-750X
Container-title:Journal of Materials Chemistry B
language:en
Short-container-title:J. Mater. Chem. B

Author:

Xu Fan¹,Li Minghua¹,Que Zujun²,Su Mingliang³,Yao Wang³,Zhang Yu³,Luo Bin¹,Li Yan¹,Zhang Zhanxia³^ORCID,Tian Jianhui¹²

Affiliation:

1. Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China

2. Institute of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, 200071, Shanghai, China

3. Institute of Traditional Chinese Medicine Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 200032, Shanghai, China

Abstract

Combined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine is a promising strategy for the treatment of non-small cell lung cancer (NSCLC) metastasis.

Funder

Natural Science Foundation of Shanghai

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering,General Chemistry,General Medicine

Link

http://pubs.rsc.org/en/content/articlepdf/2023/TB/D2TB02328H

Reference44 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Cancer statistics, 2022

3. Targeted Therapies in Early Stage NSCLC: Hype or Hope?